Description
Therapeutic indications: Akzaramer is indicated for the treatment of relapsing forms of multiple sclerosis (MS). Akzaramer is not indicated in primary or secondary progressive MS. Posology and method of administration: Posology: The recommended dosage in adults is 40 mg of Akzaramer (one pre-filled syringe), administered as a subcutaneous injection three times a week with at least 48 hours apart. At the present time, it is not known for how long the patient should be treated. A decision concerning long term treatment should be made on an individual basis by the treating physician. Paediatric population Children and adolescents: No clinical trials or pharmacokinetic studies have been conducted in children or adolescents for Akzaramer. There is not enough information available on the use of Akzaramer 40 mg/ml TIW in children and adolescents below 18 years of age to make any recommendation for its use. Therefore, Akzaramer40 mg/ ml TIW should not be used in this population. Elderly patients Akzaramer has not been specifically studied in the elderly. Patients with renal impairment Akzaramer has not been specifically studied in patients with renal impairmen. Method of administration: Patients should be instructed in self-injection techniques and should be supervised by a health-care professional the first time they self-inject and for 30 minutes after. A different site should be chosen for every injection, so this will reduce the chances of any irritation or pain at the site of the injection. Sites for self-injection include the abdomen, arms, hips and thighs.
